Navigation Links
Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Date:8/19/2007

r the Three For the Six

Months Ended Months Ended

June 30, July 1, June 30, July 1,

2007 2006 2007 2006

Revenues:

Nabi Biologics $ 20,847 $ 19,876 $ 44,614 $ 38,927

Nabi Pharmaceuticals 26 498 7 964

Total $ 20,873 $ 20,374 $ 44,621 $ 39,891

Gross margin (loss):

Nabi Biologics $ 9,192 $ 5,649 $ 18,245 $ 10,606

Nabi Pharmaceuticals 1 359 (111) 403

Total $ 9,193 $ 6,008 $ 18,134 $ 11,009

Operating income (loss):

Nabi Biologics $ 1,086 $ 155 $ 3,438 $ 693

Nabi Pharmaceuticals (2,809) (5,798) (7,735) (13,466)

Segment operating loss (1,723) (5,643) (4,297) (12,773)

CSS (6,706) (8,375) (15,260) (16,878)

Total $ (8,429) $ (14,018) $ (19,557) $ (29,651)


'/>"/>
SOURCE Nabi Biopharmaceuticals

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Sygnis Pharma AG announces date for presentation of clinical results
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2008)...O, Aug. 18 /- The next time you consi...ff, it might be worth counting sheep,instead. A se...er in San,Diego, Calif. has found evidence that ta...k of skin cancer., Daniel F. Kripke, M.D.,s artic...eeping pills and cancer, has just been published i...
(Date:8/18/2008)...iates Clinical Trials Phase of Test Development Pr...-FirstCall/ -- Beckman,Coulter, Inc. (NYSE: BEC )...y out its U.S. royalty obligation to Nephromics LL... women,s health. The license is for tests,related ...f preeclampsia, a,leading cause of maternal death....
(Date:8/17/2008)...Australia, Aug. 17 /Xinhua-...ed that the first pivotal Phase 3,clinical trial o...has,completed enrolment., The first efficacy data... the first half of 2009. The trial commenced its d...ruitment target of 250 subjects in June,2008 and c...
(Date:8/14/2008)...N, N.J., Aug. 14 /- Pharmas...aceutical company committed to,discovering, develo...l,infections, reported unaudited financial results... Pharmasset reported a net loss attributable to,co...share of $0.69 for the,quarter ended June 30, 2008...
Breaking Medicine Technology:Prescription Sleeping Pill Use Tied to Cancer 2Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers 2Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers 3Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 2Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 3Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 4Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 5Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 6Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 7Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 8Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 9Targeted Genetics Announces Positive Phase 1 2 tgAAC94 Data Presented at Annual European Congress of Rheumatology 2399 1Targeted Genetics Announces Positive Phase 1 2 tgAAC94 Data Presented at Annual European Congress of Rheumatology 2399 2Targeted Genetics Announces Positive Phase 1 2 tgAAC94 Data Presented at Annual European Congress of Rheumatology 2399 3U S District Court Finds Arthrex Guilty of Willfully Infringing Smith 26 Nephew Endoscopy Patent 21638 1U S District Court Finds Arthrex Guilty of Willfully Infringing Smith 26 Nephew Endoscopy Patent 21638 2U S District Court Finds Arthrex Guilty of Willfully Infringing Smith 26 Nephew Endoscopy Patent 21638 3Pharmaxis Long Term Safety Study of Bronchitol Completes 2398 1Pharmaxis Long Term Safety Study of Bronchitol Completes 2398 2Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 1Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 2Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 3Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 4Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 5Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 6Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 7Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 8Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 9Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 10Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 11Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 12Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 13Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 14Helix BioPharma product development update quarterly highlights and financial results for fiscal Q3 2008 5946 15
...NCISCO--(BUSINESS WIRE)--May 21, 2007 - Gilead Sci...of two long-term studies,evaluating ambrisentan, a...ERA) for the treatment of patients with pulmonary,...are from patients,who originally participated in t..., a Phase II study of patients who had,previously ...
... product recently approved by FDA for long-term,ma...ata demonstrate,first nebulized formoterol fumarat...y powder formoterol, enhanced patient quality of,l...y 20, 2007) – Data presented at the,Internat...(ATS),demonstrate that Perforomist™ (formote...
Other Medicine Technology:Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 2Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 3Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 4Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 5Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7
(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...
(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...
(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...
(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...
Breaking Medicine News(10 mins):Health News:Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use 2Health News:Medicare Advantage Plans Struggle to Comply With New Federal Law 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 3Health News:Longs Drug Stores Corporation Reports Second Quarter Results 4Health News:Longs Drug Stores Corporation Reports Second Quarter Results 5Health News:Longs Drug Stores Corporation Reports Second Quarter Results 6Health News:Longs Drug Stores Corporation Reports Second Quarter Results 7Health News:Longs Drug Stores Corporation Reports Second Quarter Results 8Health News:Longs Drug Stores Corporation Reports Second Quarter Results 9Health News:Longs Drug Stores Corporation Reports Second Quarter Results 10Health News:Longs Drug Stores Corporation Reports Second Quarter Results 11Health News:Longs Drug Stores Corporation Reports Second Quarter Results 12Health News:Longs Drug Stores Corporation Reports Second Quarter Results 13Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3
...shed yesterday looks into support props for care g... elucidates the plight of most relatives // and ca...ften the rehabilitation and restoration of confide... realms of hospital in –patient care. It is the v...
...sions for breast cancer fell by a third between 19...ncy for Healthcare Research and Quality. The decli...cilities for breast cancer surgeries, plus the gro...ns such as lumpectomies, which are typically perfo...
...survivors will be able to do away with invasive br...ch involving stem cells //extracted from their own... who are investigating the potential these cells m.... In animal models, the researchers hope to prove...
...hyam Sarda, a prime accused in the expired blood t...nior police official.// "We have arrested Ghanshy...uced in court," said Gyanwant Singh, deputy commis... department). Ghanshyam's brother, Govind Sarda,...
Other Medicine News:Health News:Breast reconstruction may be possible with fat stem cells 2
.../Cuff combines the therapeutic benefits of control...ing, and cold to minimize pain. The cuff is anatom...ing maximum cryotherapy. The Elbow Cryo/Cuff is av...c size.,All Cryo/Cuffs can be ordered as a single ...
...; ROM Elbow Orthosis features aluminum cuffs that ...r joint alignment, unique slot/screw adjustment me...l adjustments to cuff position. Cuffs are configur...with contractures.,The hinge can be locked in any...
...CTION Elbow Wrap replaces messy taping and bulky e...s experiencing epicondylitis. Preferred by doctors...y fit. Two overlay straps allow you to apply force...lds the Elbow Wrap comfortably in place. Available...
The Bledsoe Original Arm Brace is designed to handle post-op elbow arthroscopy, severe elbow strains and ligament trauma. The Bledsoe Extender Arm Brace should be used when limited R.O.M. or locked c
Medicine Products: